Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067478 · ClinicalTrials.gov registry record
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
A clinical trial, sponsored by Urovant Sciences.
- Completed
- Registry status
- 403
- Enrollment target
NCT05067478: Completed study, sponsored by Urovant Sciences.
NCT05067478 is a clinical trial that has completed, run by Urovant Sciences. The registered enrollment target is 403 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05067478 has completed, sponsored by Urovant Sciences.
- COMPLETED
- Registry status
- 403 participants
- Enrollment target
Study Summary
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.
Primary Outcome
The OAB-SAT-q is an 11-item questionnaire designed to assess participant's satisfaction with overactive bladder treatment in the clinical setting. It includes 3 subscales (satisfaction, side effects, endorsement) and 2 single-item assessments (convenience, preference), with a 4-week recall period. The OAB-SAT-q is scored by domains ranging from 0-100. Scores for the Convenience item range from 0-100. The Preference item is calculated as a percentage. Higher scores indicate higher levels of treat
Interventions
- DRUG Vibegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2024-07-26 |
What the finished NCT05067478 record still lists
NCT05067478 is an observational study that tracks outcomes without assigning an intervention. The registered 403 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Vibegron is the first listed.
NCT05067478 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05067478 about?
NCT05067478 is a clinical study titled "Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)". This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.
What is the current status of trial NCT05067478?
This trial is currently completed. The enrollment target is 403 participants. The study started on 2021-10-28. Estimated completion is 2024-07-26.
What interventions are being tested in trial NCT05067478?
The interventions under investigation include: Vibegron (DRUG).
Who is sponsoring clinical trial NCT05067478?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05647122 · 403 participants · Phase 1
First in Human Study of AZD9592 in Solid Tumors
- NCT05674799 · 403 participants · NA
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
- NCT06244771 · 403 participants · Phase 1
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI